Quick Answer
Damora Therapeutics, Inc. reported Research And Development Expense of $26.88 million for the year ending 2025.
- Damora Therapeutics, Inc. showed an increase of +320.1% in Research And Development Expense from 2024 to 2025.
- This data is from Damora Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $3.67 million | Q1 2020: $4.71 million | Q2 2020: $4.52 million | Q3 2020: $7.65 million | Q1 2021: $9.99 million | Q2 2021: $8.64 million | Q3 2021: $9.75 million | Q1 2022: $13.24 million | Q2 2022: $13.71 million | Q3 2022: $10.49 million | Q1 2023: $10.36 million | Q2 2023: $8.09 million | Q3 2023: $2.55 million | Q1 2024: $2.46 million | Q2 2024: $1.83 million | Q3 2024: $1.09 million | Q1 2025: $678.0 thousand | Q2 2025: $1.47 million | Q3 2025: $1.42 million.
- Over the full 7 years of available data (2019 to 2025), Damora Therapeutics, Inc.'s Research And Development Expense has grown by 36.2%.
- Historical annual values: Fiscal year 2025: $26.88 million | Fiscal year 2024: $6.40 million | Fiscal year 2023: $23.77 million | Fiscal year 2022: $48.21 million | Fiscal year 2021: $38.49 million | Fiscal year 2020: $24.63 million | Fiscal year 2019: $19.74 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: